Gerald B. Appel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gerald B. Appel has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Andrew S. Bomback
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
3 shared publicationsJai Radhakrishnan
Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY
2 shared publicationsAlice S. Appel
1 shared publicationAlice Sue Appel
Glomerular Kidney Disease Center Division of Nephrology College of Physicians and Surgeons Columbia University Medical Center Columbia University Room 4124 Presbyterian Hospital 622 West 168th Street 10032 New York New York N.Y NY USA
1 shared publicationAnushya Jeyabalan
Department of Medicine, Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA
1 shared publicationC L Kunis
1 shared publication
Latest Publications
- 1 August 2021
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 78 (2) , 219-225.e1
Concurrent Anti–Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series
- 1 August 2021
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 78 (2) , 219-225.e1
Concurrent Anti–Glomerular Basement Membrane Antibody Disease and Membranous Nephropathy: A Case Series
- Open Access
- 1 January 2021
- Published by Elsevier in Kidney International Reports
- Vol. 6 (1) , 239-242
Familial Fibrillary Glomerulonephritis in Living Related Kidney Transplantation
- 1 January 2021
- Published by Elsevier in Kidney International Reports
- Vol. 6 (1) , 239-242
Open AccessFamilial Fibrillary Glomerulonephritis in Living Related Kidney Transplantation
- 1 January 2017
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 84 (2) , 114-130
Thrombotic microangiopathies: Similar presentations, different therapies
Thrombotic thrombocytopenic purpura, Shiga toxin hemolytic uremic syndrome, atypical hemolytic uremic syndrome, and antiphospholipid syndrome are thrombotic microangiopathies that present similarly but arise from different causes. Management depends on distinguishing them promptly and providing targeted therapy.
- 1 January 2017
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 84 (2) , 114-130
Thrombotic microangiopathies: Similar presentations, different therapies
Thrombotic thrombocytopenic purpura, Shiga toxin hemolytic uremic syndrome, atypical hemolytic uremic syndrome, and antiphospholipid syndrome are thrombotic microangiopathies that present similarly but arise from different causes. Management depends on distinguishing them promptly and providing targeted therapy.
- 8 May 2013
- Published by S. Karger AG
- Vol. 181, 163-174
Membranoprolferative Glomerulonephritis - Mechanisms and Treatment
Membranoproliferative glomerulonephritis (MPGN) is a histologic pattern of glomerular damage with many etiologies. In the past, it was divided into secondary and primary, or idiopathic forms. In turn, the idiopathic forms were labeled MPGN types I, II, and III based on ultrastructural localization of the electron-dense ‘deposits'. A recent major change in classification relies on the presence of immunoglobulins and complement to determine etiologies that are more in line with the pathogenesis of the disease. Idiopathic MPGN II, now called dense deposit disease and C3 glomerulonephritis, are now recognized as diseases of the alternate complement pathway. They are caused by a variety of alternate complement pathway defects including genetic forms and those due to autoantibodies that either activate accelerators of the pathway or block inhibitors of the cascade. These patients need to be evaluated in a different fashion and receive different therapy than those patients with MPGN forms associated with immunoglobulin deposition.
- 8 May 2013
- Published by S. Karger AG
- Vol. 181, 163-174
Membranoprolferative Glomerulonephritis - Mechanisms and Treatment
Membranoproliferative glomerulonephritis (MPGN) is a histologic pattern of glomerular damage with many etiologies. In the past, it was divided into secondary and primary, or idiopathic forms. In turn, the idiopathic forms were labeled MPGN types I, II, and III based on ultrastructural localization of the electron-dense ‘deposits'. A recent major change in classification relies on the presence of immunoglobulins and complement to determine etiologies that are more in line with the pathogenesis of the disease. Idiopathic MPGN II, now called dense deposit disease and C3 glomerulonephritis, are now recognized as diseases of the alternate complement pathway. They are caused by a variety of alternate complement pathway defects including genetic forms and those due to autoantibodies that either activate accelerators of the pathway or block inhibitors of the cascade. These patients need to be evaluated in a different fashion and receive different therapy than those patients with MPGN forms associated with immunoglobulin deposition.
- 1 April 2013
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 80 (4) , 209-217
Detecting and controlling diabetic nephropathy: What do we know?
Diabetic nephropathy is becoming increasingly common with the aging of our population and the obesity epidemic. The major ways to prevent or slow its progression are by reducing blood pressure, controlling blood sugar, and inhibiting the renin-angiotensin-aldosterone axis. New therapeutic agents are also being tried.
- 1 April 2013
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 80 (4) , 209-217
Detecting and controlling diabetic nephropathy: What do we know?
Diabetic nephropathy is becoming increasingly common with the aging of our population and the obesity epidemic. The major ways to prevent or slow its progression are by reducing blood pressure, controlling blood sugar, and inhibiting the renin-angiotensin-aldosterone axis. New therapeutic agents are also being tried.
- Open Access
- 22 January 2013
- Published by S. Karger AG in Blood Purification
- Vol. 35 (1-3) , 81-85
New Diagnostic Tests and New Therapies for Glomerular Diseases
There has recently been considerable progress in our understanding of the pathology and mechanisms of a number of primary glomerulopathies. However, without parallel advancement in both our diagnostic skills and treatment methods, such advances cannot be translated into clinical progress. Fortunately, a number of new promising diagnostic tests are being evaluated in patients with a variety of primary glomerulopathies including focal segmental glomerulosclerosis membranous nephropathy, IgA nephropathy, and C3 glomerulopathies. Likewise, a number of new therapeutic interventions are available to treat these entities, including the pituitary hormone ACTH, the monoclonal antibody rituximab, and the monoclonal blocker of the fifth component of complement, eculizumab. All three are already FDA-approved for at least one glomerular disease. This article will discuss these newer diagnostic tests and therapies as well as their potential roles in patients with glomerular diseases and where they fit in with the rest of our therapeutic armamentarium in treating patients with glomerular diseases.
- 22 January 2013
- Published by S. Karger AG in Blood Purification
- Vol. 35 (1-3) , 81-85
Open AccessNew Diagnostic Tests and New Therapies for Glomerular Diseases
There has recently been considerable progress in our understanding of the pathology and mechanisms of a number of primary glomerulopathies. However, without parallel advancement in both our diagnostic skills and treatment methods, such advances cannot be translated into clinical progress. Fortunately, a number of new promising diagnostic tests are being evaluated in patients with a variety of primary glomerulopathies including focal segmental glomerulosclerosis membranous nephropathy, IgA nephropathy, and C3 glomerulopathies. Likewise, a number of new therapeutic interventions are available to treat these entities, including the pituitary hormone ACTH, the monoclonal antibody rituximab, and the monoclonal blocker of the fifth component of complement, eculizumab. All three are already FDA-approved for at least one glomerular disease. This article will discuss these newer diagnostic tests and therapies as well as their potential roles in patients with glomerular diseases and where they fit in with the rest of our therapeutic armamentarium in treating patients with glomerular diseases.
- 2 October 2012
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 8 (11) , 634-642
Pathogenesis of the C3 glomerulopathies and reclassification of MPGN
Until recently, membranoproliferative glomerulonephritis (MPGN) was clinically classified as either primary, idiopathic MPGN or as secondary MPGN when an underlying aetiology was identifiable. Primary MPGN was further classified into three types--type I, type II, and type III--based principally on the ultrastructural appearance and location of electron-dense deposits. Both the clinical and histopathologic schemes presented problems, however, as neither was based on disease pathogenesis. An improved understanding of the role of complement in the pathogenesis of MPGN has led to a proposed reclassification into immunoglobulin-mediated disease (driven by the classical complement pathway) and non-immunoglobulin-mediated disease (driven by the alternative complement pathway). This reclassification has led to improved diagnostic clinical algorithms and the emergence of a new grouping of diseases known as the C3 glomerulopathies, best represented by dense deposit disease and C3 glomerulonephritis. In this Review, we re-examine the previous and current classification schemes of MPGN, focusing on the role of complement. We survey current data about the pathogenesis of the C3 glomerulopathies, including familial studies and patient cohorts from the USA and Europe. In addition, we discuss the diagnosis, treatment, and prognosis of the C3 glomerulopathies.
- 2 October 2012
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 8 (11) , 634-642
Pathogenesis of the C3 glomerulopathies and reclassification of MPGN
Until recently, membranoproliferative glomerulonephritis (MPGN) was clinically classified as either primary, idiopathic MPGN or as secondary MPGN when an underlying aetiology was identifiable. Primary MPGN was further classified into three types--type I, type II, and type III--based principally on the ultrastructural appearance and location of electron-dense deposits. Both the clinical and histopathologic schemes presented problems, however, as neither was based on disease pathogenesis. An improved understanding of the role of complement in the pathogenesis of MPGN has led to a proposed reclassification into immunoglobulin-mediated disease (driven by the classical complement pathway) and non-immunoglobulin-mediated disease (driven by the alternative complement pathway). This reclassification has led to improved diagnostic clinical algorithms and the emergence of a new grouping of diseases known as the C3 glomerulopathies, best represented by dense deposit disease and C3 glomerulonephritis. In this Review, we re-examine the previous and current classification schemes of MPGN, focusing on the role of complement. We survey current data about the pathogenesis of the C3 glomerulopathies, including familial studies and patient cohorts from the USA and Europe. In addition, we discuss the diagnosis, treatment, and prognosis of the C3 glomerulopathies.
- 1 February 2012
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 79 (2) , 134-140
New and future therapies for lupus nephritis
Clinical trials show that less-toxic drugs, such as mycophenolate mofetil, are as effective as older, more-toxic ones.
- 1 February 2012
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 79 (2) , 134-140
New and future therapies for lupus nephritis
Clinical trials show that less-toxic drugs, such as mycophenolate mofetil, are as effective as older, more-toxic ones.
- Open Access
- 1 December 2010
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 21 (12) , 2028-2035
Updates on the Treatment of Lupus Nephritis
The treatment of lupus nephritis has changed significantly over the past decade in large part because of data from well-conducted randomized clinical trials. The concept of two phases of therapy—induction and maintenance—is widely accepted. The histopathologic classification of lupus nephritis continues to guide therapy, and treatment for all major classes of lupus nephritis has seen some shift in management during this time. New regimens using lower doses and shorter treatment durations of intravenous cyclophosphamide have been advanced to reduce toxicity without sacrificing efficacy of therapy. Mycophenolate mofetil has emerged as a viable alternative to cyclophosphamide for induction therapy of both proliferative and membranous lupus nephritis. Combination induction treatment with multiple agents has also been successful. Large controlled trials using mycophenolate mofetil and azathioprine for maintenance therapy have been performed. Here, we review recent additions to the growing body of literature on how to most effectively treat lupus nephritis with the least amount of toxicity. We discuss new treatment strategies currently being explored in clinical trials.
- 1 December 2010
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 21 (12) , 2028-2035
Open AccessUpdates on the Treatment of Lupus Nephritis
The treatment of lupus nephritis has changed significantly over the past decade in large part because of data from well-conducted randomized clinical trials. The concept of two phases of therapy—induction and maintenance—is widely accepted. The histopathologic classification of lupus nephritis continues to guide therapy, and treatment for all major classes of lupus nephritis has seen some shift in management during this time. New regimens using lower doses and shorter treatment durations of intravenous cyclophosphamide have been advanced to reduce toxicity without sacrificing efficacy of therapy. Mycophenolate mofetil has emerged as a viable alternative to cyclophosphamide for induction therapy of both proliferative and membranous lupus nephritis. Combination induction treatment with multiple agents has also been successful. Large controlled trials using mycophenolate mofetil and azathioprine for maintenance therapy have been performed. Here, we review recent additions to the growing body of literature on how to most effectively treat lupus nephritis with the least amount of toxicity. We discuss new treatment strategies currently being explored in clinical trials.
- 1 April 2008
- Published by Elsevier in Kidney International
- Vol. 73 (8) , 905-907
The treatment of acute interstitial nephritis: More data at last
- 1 April 2008
- Published by Elsevier in Kidney International
- Vol. 73 (8) , 905-907
The treatment of acute interstitial nephritis: More data at last